We are a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies.
Our primary operations are focused on developing our lead therapeutic candidate, PAS-004, a next-generation macrocyclic MEK inhibitor for potential use in a range of indications, including neurofibromatosis type 1--associated plexiform neurofibromas and certain oncology indications.
Sector:
Healthcare
Industry:
Pharmaceutical and Medicine Manufacturing
Investor Relations
Growth Cap Report
Patrick Gaynes
T: +1 310 989-5666
patrick.gaynes@growthcapreport.com
Company Contact
Pasithea Therapeutics Corp.
1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
T: 305-493-8080
info@pasithea.com